Affichage 1 à 7 des 7 essais cliniques
ESSAI CLINIQUE No essai ClinicalTrials.gov ID |
Investigateur(trice) principal(e)
Coordonnateur(rice) |
||
---|---|---|---|
(EN) A Phase 1/2 Study to Evaluate the Safety and Efficacy of MK-2870 Monotherapy or in Combination With Other Anticancer Agents in Gastrointestinal Cancers
MK-9999-02A NCT06428409 ![]() |
CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
|
Colorectal Pancréas Voies biliaires |
Dre Francine Aubin Adeline Hamon 514-890-8000 poste 30737 |
(EN) A Phase 1/2 Study to Evaluate the Safety and Efficacy of MK-2870 Monotherapy or in Combination With Other Anticancer Agents in Gastrointestinal Cancers
MK-9999-02A NCT06428409 ![]() |
CENTRE UNIVERSITAIRE DE SANTE MCGILL
![]() |
Colorectal Pancréas Voies biliaires |
Dre Victoria Mandilaras Rodrigo Skowronski 514-934-1934 poste 36275 |
(EN) A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 193 in Combination With Other Therapies in Subjects With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous MTAP-deletion
20230223 NCT06360354 ![]() |
CHU DE QUEBEC – UNIVERSITE LAVAL
![]() |
Pancréas Voies biliaires |
Dr Maxime Chénard-Poirier Maryse Gingras 418-525-4444 poste 15781 |
(EN) A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Global Study of Rilvegostomig in Combination With Chemotherapy as Adjuvant Treatment After Resection of Biliary Tract Cancer With Curative Intent
ARTEMIDE-Biliary01 NCT06109779 ![]() |
CHU DE QUEBEC – UNIVERSITE LAVAL
![]() |
Voies biliaires |
Dr Maxime Chénard-Poirier Alice Ndayizigiye 418-525-4444 poste 15782 |
Profilage moléculaire complet des cancers des voies biliaires de stade avancé pour une meilleure sélection des traitements : une étude du Centre universitaire de santé McGill
COMPASS-B-MUHC NCT04318834 ![]() |
CENTRE UNIVERSITAIRE DE SANTE MCGILL
![]() |
Voies biliaires |
Dr George Zogopoulos Crystal Haigh 514-934-1934 poste 76333 |
(EN) A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Global Study of Rilvegostomig in Combination With Chemotherapy as Adjuvant Treatment After Resection of Biliary Tract Cancer With Curative Intent
ARTEMIDE-Biliary01 NCT06109779 ![]() |
CENTRE UNIVERSITAIRE DE SANTE MCGILL
![]() |
Voies biliaires |
Dr Jamil Asselah Amanda McFarlan 514-934-1934 poste 44205 |
(EN) A Phase 3 Study of Trastuzumab Deruxtecan (T-DXd) and Rilvegostomig Versus Standard-of-Care Gemcitabine, Cisplatin, and Durvalumab for First Line Locally Advanced or Metastatic HER2-expressing Biliary Tract Cancer
DESTINY-Biliary Tract Cancer-01 NCT06467357 ![]() |
CENTRE UNIVERSITAIRE DE SANTE MCGILL
![]() |
Voies biliaires |
Dre Victoria Mandilaras Amanda McFarlan 514-934-1934 poste 44205 |